Anxiolytics

Kaival Brands Innovations Group, Inc. (OTCQB: KAVL) Acquires U.S. Patent and International Patent Applications to Produce Nicotine Cessation Products

Retrieved on: 
Monday, September 28, 2020
Psychoactive drugs, Smoking, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine

Kaival Brands is also pleased to announce the formation of a new wholly-owned subsidiary, Kaival Labs, Inc., a Delaware corporation ( Kaival Labs ), that will own and develop the patent.

Key Points: 
  • Kaival Brands is also pleased to announce the formation of a new wholly-owned subsidiary, Kaival Labs, Inc., a Delaware corporation ( Kaival Labs ), that will own and develop the patent.
  • The exclusivity is that the patents allow us to control the specific ratios of each isomer in the final synthetic nicotine molecule we produce for cessation products.
  • Kaival Labs, Inc., the latest addition to Kaival Brands Innovations Group, Inc., is a wholly-owned subsidiary.
  • To learn more about Kaival Labs, its advocacies, and how isomer-specific synthetic nicotine can help curb nicotine addiction, visit www.kaivallabs.com .

Kaival Brands Innovations Group, Inc. (OTCQB: KAVL) Acquires U.S. Patent and International Patent Applications to Produce Specialized Synthetic Nicotine Cessation Products

Retrieved on: 
Monday, September 28, 2020
Psychoactive drugs, Smoking, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine

Kaival Brands is also pleased to announce the formation of a new wholly-owned subsidiary, Kaival Labs, Inc., a Delaware corporation ( Kaival Labs ), that will own and develop the patent.

Key Points: 
  • Kaival Brands is also pleased to announce the formation of a new wholly-owned subsidiary, Kaival Labs, Inc., a Delaware corporation ( Kaival Labs ), that will own and develop the patent.
  • The exclusivity is that the patents allow us to control the specific ratios of each isomer in the final synthetic nicotine molecule we produce for cessation products.
  • Kaival Brands will acquire the patent and international patent applications for a total purchase price of $3 million from Next Generation Labs, LLC, (NGL) the only specialized manufacturer of the patented TFN brand synthetic nicotine in the United States.
  • To learn more about Kaival Labs, its advocacies, and how isomer-specific synthetic nicotine can help curb nicotine addiction, visit www.kaivallabs.com .

Dr. Reddy's announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market

Retrieved on: 
Friday, September 25, 2020
General Health, Pharmaceutical, Health, Imidazoles, Drugs, Veterinary drugs, Anxiolytics, Dexmedetomidine, Dr. Reddy's Laboratories, Medetomidine, Companies, Health care

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutic equivalent generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA).
  • Our ability to adequately supply Dexmedetomidine is important for patients as it is on the FDAs Drug Shortage list.
  • The Precedex in 0.9% Sodium Chloride Injection brand and generic market had U.S. sales of approximately $210 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
  • Dr. Reddys Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection is available in 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL) in 50 mL and 100 mL clear glass vials, respectively.

COVID-19 Recovery Analysis: Alcoholic Beverages Market in US|New Product Launches to Boost the Market Growth | Technavio

Retrieved on: 
Wednesday, September 16, 2020
Retail, Food, Beverage, Wine & Spirits, Psychoactive drugs, Neurochemistry, Drugs, Drinking culture, Alcohols, Anxiolytics

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • New product launches has been instrumental in driving the growth of the market.
  • However, increasing cases of accidents due to driving under the influence of alcohol might hamper the market growth.
  • Download a Free Sample Report on COVID-19 Impacts
    Alcoholic beverages market in US 2020-2024: Segmentation
    Alcoholic beverages market in US is segmented as below:

VELO Launches Adult Nicotine Consumer-Focused E-Commerce Website, shop.velo.com

Retrieved on: 
Thursday, August 27, 2020
Psychoactive drugs, Tobacco, Smoking, Electronic cigarettes, Smoking cessation, Alkaloids found in Erythroxylum coca, Anxiolytics, Nicotine, Velo

The platform is designed to enable age 21+ adult nicotine consumers (ANCs) to identify and purchase the modern oral products they are looking for.

Key Points: 
  • The platform is designed to enable age 21+ adult nicotine consumers (ANCs) to identify and purchase the modern oral products they are looking for.
  • Through the site, age 21+ adult nicotine consumers will have the opportunity to learn about VELO products; interact with the brand and engage across channels; and now shop online to purchase their ideal modern oral product.
  • "Today's adult nicotine consumers are looking for unique products that fit their modern-day lives, so VELO offers a portfolio of product options with adult nicotine consumer moments in mind," said Amy Harp, vice president digital marketing and e-commerce.
  • The release of the e-commerce website marks a major step for the Company's digital-first initiative to reach adult nicotine consumers where they are.

"A journey to simplify you" A lifestyle of mindfulness with Japanese green tea

Retrieved on: 
Tuesday, August 18, 2020
Glutamate neurotransmitter), Japanese tea, Psychoactive drugs, Chinese tea, Food and drink, Korean tea, Anxiolytics, Theanine, Green tea, Tea

Marie Kondo regularly drinks Japanese green tea and has had a close relationship with the drink from a young age.

Key Points: 
  • Marie Kondo regularly drinks Japanese green tea and has had a close relationship with the drink from a young age.
  • Together with actress Nikki Reed, the Twilight Saga star and owner of sustainable lifestyle brand, Bayou with Love, they will introduce the wonderful world of Japanese green tea.
  • The promotion will kick off with a campaign video that will show the audience how to simplify their life and mind with Japanese green tea.
  • Due to millennials interest in mindfulness, the campaign draws attentions to Japanese green tea and its high concentration of theanine.

VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder

Retrieved on: 
Thursday, July 23, 2020
Psychiatry, Anxiety disorders, Psychiatric diagnosis, Psychology, RTT, Anxiolytics, Abnormal psychology, 4-Androstadienol, Social anxiety disorder, Anxiety, Social anxiety, Generalized anxiety disorder

Food and Drug Administration(FDA) regarding Phase 3 development of PH94B for the acute treatment of anxiety in adult patients with social anxiety disorder (SAD).

Key Points: 
  • Food and Drug Administration(FDA) regarding Phase 3 development of PH94B for the acute treatment of anxiety in adult patients with social anxiety disorder (SAD).
  • PH94B is an investigational rapid-onset neurosteroid nasal spray that is fundamentally differentiated from all FDA-approved treatments for anxiety disorders.
  • As in the successful Phase 2 study of PH94B in SAD, the study will involve a single laboratory-simulated anxiety-provoking public speaking challenge.
  • VistaGen is preparing for Phase 3 clinical development of PH94B as a potentialnew generation fast-acting, non-sedating, non-addictive acute treatment of anxiety in adults with social anxiety disorder (SAD).

Global Crown Caps Market Outlook (2018 to 2027) - Strategic Recommendations for New Entrants - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 16, 2020
Packaging, Retail, Manufacturing, Food, Beverage, Psychoactive drugs, Drinks, Alcoholic drink, Anxiolytics, Drinking culture

The "Crown Caps - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Crown Caps - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Crown Caps Market is expected to grow at a CAGR of 5.0% during the forecast period.
  • High demand for alcoholic and carbonated drinks and rising introduction of improved packaging designs are the major factors driving the market growth.
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
    Company profiling with detailed strategies, financials, and recent developments

Global Alcoholic Drinks Market 2020-2024 | Evolving Opportunities with Anheuser Busch InBev SA/NV and Bacardi Global Brands Ltd. | Technavio

Retrieved on: 
Thursday, July 9, 2020
Retail, Food, Beverage, Wine & Spirits, Psychoactive drugs, Alcoholic drinks, Drinking culture, Anxiolytics, Drug culture, Drink

The global alcoholic drinks market is expected to grow by 18.88 bn liters as per Technavio.

Key Points: 
  • The global alcoholic drinks market is expected to grow by 18.88 bn liters as per Technavio.
  • In addition, the demand for lighter alcoholic beverages that pose fewer health risks is anticipated to boost the growth of the alcoholic drinks market.
  • In addition, the demand for premium alcoholic drinks has been growing faster in comparison to regular priced alcoholic drinks.
  • Therefore, the increasing focus on product premiumization is one of the key factors driving the growth of the global alcoholic drinks market.

BioXcel Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Formulation for BXCL501 and Methods of Treating Agitation

Retrieved on: 
Tuesday, July 7, 2020
Branches of biology, Drugs, Enantiopure drugs, Chemistry, Anxiolytics, Dexmedetomidine, Imidazoles, Orange Book, Dex, Agonist

The patent is expected to cover film formulations containing Dex and methods of treating agitation using such film formulations.

Key Points: 
  • The patent is expected to cover film formulations containing Dex and methods of treating agitation using such film formulations.
  • A Notice of Allowance is issued after the USPTO makes a determination that a patent should be granted from an application.
  • After issuance, BioXcel plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
  • BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation.